494 related articles for article (PubMed ID: 32183332)
21. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
22. Immunological aspects and anti-amyloid strategy for Alzheimer's dementia.
Liščić RM
Arh Hig Rada Toksikol; 2013 Dec; 64(4):603-8. PubMed ID: 24384767
[TBL] [Abstract][Full Text] [Related]
23. [Biomarker and imaging of Alzheimer's disease].
Kawarabayashi T; Shoji M
No To Shinkei; 2005 Oct; 57(10):839-52. PubMed ID: 16277229
[No Abstract] [Full Text] [Related]
24. Biomarkers for Alzheimer's disease: current status and prospects for the future.
Blennow K; Zetterberg H
J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
[TBL] [Abstract][Full Text] [Related]
25. Imaging as a strategy for premortem diagnosis and staging of tauopathies.
Kim S; Jensen JR; Cisek K; Funk KE; Naphade S; Schafer K; Kuret J
Curr Alzheimer Res; 2010 May; 7(3):230-4. PubMed ID: 20088805
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
27. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers reflecting different facets of Alzheimer's disease.
Zetterberg H
Eur J Neurol; 2008 Nov; 15(11):1143-4. PubMed ID: 18973609
[No Abstract] [Full Text] [Related]
30. [Expression of proteins related neurodegeneration in autopsy brains of the aged].
Zhu M; Meng X; Wang L; Hu Y; Zhang H; Han Z
Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):651-6. PubMed ID: 25567589
[TBL] [Abstract][Full Text] [Related]
31. Laboratory biomarkers in Alzheimer's disease.
Steinerman JR; Honig LS
Curr Neurol Neurosci Rep; 2007 Sep; 7(5):381-7. PubMed ID: 17764627
[TBL] [Abstract][Full Text] [Related]
32. Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease.
Lehmann S; Delaby C; Paquet C; Gabelle A
Clin Chem Lab Med; 2015 Jul; 53(8):e175-7. PubMed ID: 25870963
[No Abstract] [Full Text] [Related]
33. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
[TBL] [Abstract][Full Text] [Related]
34. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J; Schild A; Hoerndli F; Pennanen L
Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
[TBL] [Abstract][Full Text] [Related]
35. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R
Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers of Alzheimer's disease: the present and the future.
Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease.
Ballard C; Gauthier S; Corbett A; Brayne C; Aarsland D; Jones E
Lancet; 2011 Mar; 377(9770):1019-31. PubMed ID: 21371747
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
40. An ideal biological marker of Alzheimer's disease: dream or reality?
Rípová D; Strunecká A
Physiol Res; 2001; 50(2):119-29. PubMed ID: 11522040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
